Accelerating Healthcare Research in the UK
NVIDIA launched the UK’s most powerful supercomputer, enabling top scientists and healthcare experts to use the powerful combination of AI and simulation to speed the digital biology revolution and bolster the country’s world-leading life sciences industry.
Having trouble viewing this video? Watch it here.
UK healthcare startups can now apply for access to Cambridge-1. The selected companies will be announced in early 2022, offering them access to the UK’s most powerful supercomputer and NVIDIA Inception benefits, as well as the opportunity to meet with Cambridge-1’s founding partners.
Dedicated to advancing healthcare through digital biology, Cambridge-1’s first projects with AstraZeneca, GSK, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, and Oxford Nanopore include developing a deeper understanding of dementia, cancer, and other serious diseases, as well as accelerating drug discovery and genome sequencing.
AstraZeneca
AstraZeneca is powering modern machine learning (ML) and AI to accelerate drug discovery with Cambridge-1, training models to learn the grammar of chemistry, and processing whole slide digital pathology images.
GSK
AI is critical for unlocking the value of human genetics. With the computational resources of Cambridge-1, GSK is using advanced ML to harness genetic evidence in large databases and develop transformative medicine.
King's College London
King’s College London is building deep learning models that can synthesize artificial 3D MRI images of human brains. Cambridge-1 enables accelerated generation of this synthetic data so researchers can understand how different factors affect the brain, anatomy, and pathology.
NHS - Founding Partner
Processing, handling, and reacting to large amounts of patient data from disparate systems is a key challenge for Guy’s and St Thomas’ NHS Foundation Trust. The NHS uses AI technologies that require supercomputing power to analyze and clean the data.
Oxford Nanopore - Founding Partner
Oxford Nanopore is further accelerating its research with Cambridge-1, enabling its algorithms team to achieve same day results that accelerate research with more powerful and impactful genomics applications.
Peptone
Peptone aims to change the way protein drugs are engineered using unsupervised learning and reinforcement learning techniques. It plans to use Cambridge-1 to design antibodies that could help treat several inflammatory disorders.
Cambridge-1 brings together decades of NVIDIA work in accelerated computing, AI, and life sciences into a single system: an NVIDIA DGX SuperPOD™ supercomputing cluster. Cambridge-1, powered by 100% renewable energy, now ranks among the world’s 50 fastest supercomputers.
NVIDIA DGX SuperPOD delivers a turnkey AI data center solution that allows researchers to focus on insights instead of infrastructure. A full-stack data center platform with best-of-breed computing, network fabric, storage, and software tools, along with a white-glove implementation service, ensures results in weeks instead of months. Learn more about the technology powering Cambridge-1.
Sign up for the latest NVIDIA healthcare news, including updates on Cambridge-1.